Developmental Research Program

发展研究计划

基本信息

批准号：
10269646
负责人：
Jean-Pierre J. Issa
金额：
$ 7.99万
依托单位：
CORIELL INSTITUTE FOR MEDICAL RESEARCH
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-08-16 至 2026-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10269646
关键词：
American Association of Cancer Research Award Cancer Patient Clinical Clinical Research Clinical Trials Collaborations Communication Development Dreams Ensure Epigenetic Process Fostering Funding Goals Grant Hematologic Neoplasms Institutes Institution Laboratory Research Leadership Letters Mainstreaming Malignant Neoplasms Mission Modeling Monitor Nature Peer Review Pilot Projects Process Quality of life Recording of previous events Research Research Peer Review Research Personnel Research Project Grants Scientist Seeds Selection Criteria Solid Neoplasm Source Structure Therapeutic Studies Time Translating Translational Research University of Texas M D Anderson Cancer Center cancer therapy clinically relevant epigenetic therapy flexibility high reward high risk improved innovation leukemia novel novel therapeutic intervention pre-clinical programs research study success

项目摘要

PROJECT SUMMARY (Developmental Research Program) The specific objectives of the Developmental Research Program are to: 1. Publicize the availability of funds for pilot translational research studies in the field of Epigenetic Therapy for cancers. 2. Identify through this mechanism innovative projects with significant potential for developing and improving Epigenetic Therapies for cancers. 3. Encourage collaborations of projects with scientists within the SPORE and outside the SPORE, specifically the Van Andel Institute-Stand Up To Cancer Epigenetics Dream Team (VAI-SU2C). 4. Enhance the communication between the SPORE leaders and VAI-SU2C Investigators to encourage the development of innovative epigenetics therapies for cancer. 5. Ensure program flexibility so that developmental projects that show promise can be: 1) funded for a second year; 2) encouraged to apply for peer-reviewed funding (i.e. R01); or 3) expanded to become full SPORE projects. The structure and processes of this program are modeled after a long-standing and successful Developmental Research Program within the MDACC Leukemia SPORE, and on the success of the VAI-SU2C Epigenetics Dream Team in soliciting, reviewing, awarding and monitoring developmental research project proposals. To achieve our aims, we will establish 1) specific criteria for selection and funding through a peer review mechanism, and 2) mechanisms for close monitoring of, and collaboration between the SPORE leaders and program awardees to enhance the quality of the translational research goals.

项目摘要（发展研究计划）发展研究计划的具体目标是： 1. 公布表观遗传治疗领域试点转化研究的资金可用性对于癌症。 2. 通过该机制识别具有重大发展和改进潜力的创新项目癌症的表观遗传疗法。 3. 鼓励与 SPORE 内外科学家的项目合作，特别是范安德尔研究所 - 抗击癌症表观遗传学梦之队 (VAI-SU2C)。 4. 加强 SPORE 领导和 VAI-SU2C 调查员之间的沟通，以鼓励开发创新的癌症表观遗传学疗法。 5. 确保计划的灵活性，以便有希望的开发项目能够： 1) 资助第二年； 2) 鼓励申请同行评审资助（即R01）；或 3) 扩展至完整孢子项目。该计划的结构和流程是以长期且成功的发展为蓝本的 MDACC 白血病 SPORE 内的研究计划以及 VAI-SU2C 表观遗传学的成功梦之队征集、审查、授予和监控发展研究项目提案。到为了实现我们的目标，我们将建立 1) 通过同行评审机制选择和资助的具体标准， 2) SPORE 领导者和项目之间的密切监控和协作机制获奖者以提高转化研究的质量为目标。